The blood-brain barrier (BBB) constitutes a microvascular network responsible for excluding
most drugs from the brain. Treatment of brain tumors is limited by the impermeability of the …

Malignant brain tumors are difficult to manage clinically and are associated with high rates of
morbidity and mortality. Late diagnosis and the limitations of conventional therapies that may …

Intense research has led to a more comprehensive understanding of cancer at the genetic,
molecular, and cellular levels providing an avenue for methods of increasing antitumor …

Brain tumors are a diverse group of neoplasms that often carry a poor prognosis for patients.
Despite tremendous efforts to develop diagnostic tools and therapeutic avenues, the …

Glioblastoma multiforme (GBM) is one of the most deadly diseases that affect humans, and it
is characterized by high resistance to chemotherapy and radiotherapy. Its median survival is …

The blood–brain barrier (BBB) maintains the integrity and homeostasis of the central
nervous system (CNS) yet represents an intimidating hurdle for efficient drug delivery to …

The diagnosis and treatment of cancer or tumor at the cellular level will be greatly improved
with the development of techniques that enable the delivery of analyte probes and …

High-grade gliomas are still characterized by a poor prognosis, despite recent advances in
surgical treatment. Chemotherapy is currently practiced after surgery, but its efficacy is …

The blood–brain barrier (BBB) is meant to protect the brain from noxious agents; however, it
also significantly hinders the delivery of therapeutics to the brain. Several strategies have …

The existence of blood–brain barrier (BBB) hampers the effective treatment of central
nervous system (CNS) diseases. Almost all macromolecular drugs and more than 98% of …